Free Trial
NASDAQ:GDRX

GoodRx (GDRX) Stock Price, News & Analysis

GoodRx logo
$2.92 -0.05 (-1.68%)
Closing price 05/29/2026 04:00 PM Eastern
Extended Trading
$2.93 +0.01 (+0.24%)
As of 05/29/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About GoodRx Stock (NASDAQ:GDRX)

Advanced

Key Stats

Today's Range
$2.88
$3.01
50-Day Range
$1.91
$2.97
52-Week Range
$1.77
$5.81
Volume
1.99 million shs
Average Volume
1.91 million shs
Market Capitalization
$1.00 billion
P/E Ratio
48.67
Dividend Yield
N/A
Price Target
$3.81
Consensus Rating
Hold

Company Overview

GoodRx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
78th Percentile Overall Score

GDRX MarketRank™: 

GoodRx scored higher than 78% of companies evaluated by MarketBeat, and ranked 165th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GoodRx has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 5 buy ratings, 7 hold ratings, and 3 sell ratings.

  • Upside Potential

    GoodRx has a consensus price target of $3.81, representing about 30.6% upside from its current price of $2.92.

  • Amount of Analyst Coverage

    GoodRx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about GoodRx's stock forecast and price target.
  • Earnings Growth

    Earnings for GoodRx are expected to grow by 17.65% in the coming year, from $0.17 to $0.20 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GoodRx is 48.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.92.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GoodRx is 48.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.31.

  • Price to Earnings Growth Ratio

    GoodRx has a PEG Ratio of 1.90. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    GoodRx has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about GoodRx's valuation and earnings.
  • Percentage of Shares Shorted

    3.38% of the float of GoodRx has been sold short.
  • Short Interest Ratio / Days to Cover

    GoodRx has a short interest ratio ("days to cover") of 5.01.
  • Change versus previous month

    Short interest in GoodRx has recently increased by 42.93%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    GoodRx does not currently pay a dividend.

  • Dividend Growth

    GoodRx does not have a long track record of dividend growth.

  • News Sentiment

    GoodRx has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for GoodRx this week, compared to 4 articles on an average week.
  • Search Interest

    12 people have searched for GDRX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added GoodRx to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GoodRx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    5.87% of the stock of GoodRx is held by insiders.

  • Percentage Held by Institutions

    63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about GoodRx's insider trading history.
Receive GDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GDRX Stock News Headlines

Musk declares war on AI rivals
SpaceX and xAI just completed a $1.25 trillion merger - and Musk may no longer need data centers from Microsoft, Amazon, or Google. Tech expert and angel investor Jeff Brown has identified one chipmaker, 148 times smaller than NVIDIA, that is set to supply Musk with 5 billion chips over the next two years. Brown brings decades of senior executive experience at Qualcomm, Juniper Networks, and NXP Semiconductors to this call.tc pixel
GoodRx Earnings Call Highlights Pharma Direct Momentum
See More Headlines

GDRX Stock Analysis - Frequently Asked Questions

GoodRx's stock was trading at $2.71 at the beginning of the year. Since then, GDRX stock has increased by 7.7% and is now trading at $2.92.

GoodRx Holdings, Inc. (NASDAQ:GDRX) posted its quarterly earnings results on Wednesday, May, 6th. The company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07. The business's revenue was down 4.4% compared to the same quarter last year.
Read the conference call transcript
.

GoodRx (GDRX) raised $900 million in an IPO on Wednesday, September 23rd 2020. The company issued 34,615,384 shares at $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers.

Top institutional shareholders of GoodRx include Renaissance Technologies LLC (0.95%), Dimensional Fund Advisors LP (0.72%), Assenagon Asset Management S.A. (0.15%) and State of Wyoming (0.05%). Insiders that own company stock include Scott Wagner and Equity Vii LP Spectrum.
View institutional ownership trends
.

Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GoodRx investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
5/06/2026
Today
5/30/2026
Next Earnings (Estimated)
8/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Services
Sub-Industry
Business Services
Current Symbol
NASDAQ:GDRX
CIK
1809519
Fax
N/A
Employees
950
Year Founded
2011

Price Target and Rating

High Price Target
$6.00
Low Price Target
$2.75
Potential Upside/Downside
+30.6%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.06
Trailing P/E Ratio
48.67
Forward P/E Ratio
17.18
P/E Growth
1.9
Net Income
$30.44 million
Net Margins
2.61%
Pretax Margin
5.78%
Return on Equity
7.90%
Return on Assets
3.23%

Debt

Debt-to-Equity Ratio
0.78
Current Ratio
1.47
Quick Ratio
1.47

Sales & Book Value

Annual Sales
$787.89 million
Price / Sales
1.27
Cash Flow
$0.39 per share
Price / Cash Flow
7.42
Book Value
$1.82 per share
Price / Book
1.60

Miscellaneous

Outstanding Shares
342,574,000
Free Float
322,465,000
Market Cap
$1.00 billion
Optionable
Optionable
Beta
1.54

Social Links

The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:GDRX) was last updated on 5/30/2026 by MarketBeat.com Staff.
From Our Partners